PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 172 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,687,030 | -24.0% | 120,177 | -0.8% | 0.00% | -50.0% |
| Q2 2023 | $4,853,319 | +99721.5% | 121,121 | +1.7% | 0.00% | 0.0% |
| Q1 2023 | $4,862 | -24.6% | 119,136 | -28.7% | 0.00% | 0.0% |
| Q4 2022 | $6,447 | -100.0% | 166,980 | -57.8% | 0.00% | -77.8% |
| Q3 2022 | $21,029,000 | -9.4% | 395,350 | -0.8% | 0.01% | 0.0% |
| Q2 2022 | $23,223,000 | -22.3% | 398,340 | -3.2% | 0.01% | -10.0% |
| Q1 2022 | $29,905,000 | +19.5% | 411,686 | -1.0% | 0.01% | +42.9% |
| Q4 2021 | $25,025,000 | +21.9% | 415,903 | +13.5% | 0.01% | +16.7% |
| Q3 2021 | $20,521,000 | -6.3% | 366,442 | +1.6% | 0.01% | -14.3% |
| Q2 2021 | $21,892,000 | +20.7% | 360,779 | +39.5% | 0.01% | +16.7% |
| Q1 2021 | $18,131,000 | +9.2% | 258,677 | -6.7% | 0.01% | 0.0% |
| Q4 2020 | $16,599,000 | +15.9% | 277,394 | +16.5% | 0.01% | 0.0% |
| Q3 2020 | $14,320,000 | +10.2% | 238,190 | -3.8% | 0.01% | +20.0% |
| Q2 2020 | $12,992,000 | -2.4% | 247,598 | -37.6% | 0.01% | -16.7% |
| Q1 2020 | $13,309,000 | -39.7% | 396,925 | -18.5% | 0.01% | -25.0% |
| Q4 2019 | $22,062,000 | -34.4% | 487,026 | -44.9% | 0.01% | -42.9% |
| Q3 2019 | $33,639,000 | -11.2% | 883,624 | +1.4% | 0.01% | -6.7% |
| Q2 2019 | $37,881,000 | +1767.0% | 871,027 | +1860.1% | 0.02% | +15.4% |
| Q4 2017 | $2,029,000 | +37.6% | 44,438 | +13.1% | 0.01% | +30.0% |
| Q3 2017 | $1,475,000 | +11.2% | 39,290 | +41.2% | 0.01% | +11.1% |
| Q2 2017 | $1,327,000 | -86.0% | 27,819 | -84.5% | 0.01% | -82.0% |
| Q1 2016 | $9,487,000 | +15.4% | 179,063 | +67.3% | 0.05% | +19.0% |
| Q4 2015 | $8,219,000 | +170.5% | 107,029 | +149.1% | 0.04% | +162.5% |
| Q2 2015 | $3,038,000 | -76.2% | 42,967 | -70.1% | 0.02% | -77.1% |
| Q1 2015 | $12,763,000 | -18.8% | 143,643 | -19.0% | 0.07% | -20.5% |
| Q4 2014 | $15,727,000 | +545.3% | 177,386 | +605.4% | 0.09% | +486.7% |
| Q3 2014 | $2,437,000 | +182.4% | 25,147 | +167.6% | 0.02% | +200.0% |
| Q2 2014 | $863,000 | – | 9,396 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |